

[News Center](#)
[Newsletter](#)
[Announcements](#)
[Meetings](#)
[Archives](#)
[Contact](#)

Indiana CTSI hosts 7th annual meeting with keynote by global research leader

The Indiana Clinical and Translational Sciences Institute hosted its seventh annual meeting on Friday, Sept. 11, with 2015 August M. Watanabe Prize in Translational Medicine award winner, Carl H. June, M.D., presenting the keynote address on immune- and cell-based therapies.

To view video of the entire event, including presenter slides, [click here](#). Read about the presenters and topics, and download full presentation slides below.

To view photos of the event, visit the [IU School of Medicine Facebook page](#).



Regulation of Host Immunity to Viral Infections: Approaching Translational Science from Basic Research

Jie Sun, Ph.D.
 Assistant Professor of Pediatrics
 Indiana University School of Medicine

In his presentation, Jie Sun, Ph.D., Watanabe Translational Prize Scholar winner, covered regulation of T cell responses to influenza/RSV and the implications on neonatal/aging immunity; pulmonary macrophage responses to influenza/RSV and the implications of virus infection in hosts with pre-existing conditions such as obesity, COPD and BPD; and transcriptional regulation of innate resistance to HIV infection in CD4 T cells (Tfh, follicular helper T cells). His conclusion: BCL-6 expression in Tfh cells inhibits cell-intrinsic anti-HIV innate immunity.

[SEE SLIDES FROM DR. SUN'S PRESENTATION](#)

Too Much of a Good Thing: How Blocking Leukotriene B4 Improves Host Defense in Diabetes

C. Henrique Serezani, Ph.D.
 Assistant Professor
 Indiana University School of Medicine

By examining the factors that cause impaired host defense against diabetes, C. Henrique Serezani, Ph.D., Watanabe Translational Prize Scholar winner, provides evidence, data and skin samples to reach the following conclusions: diabetic mice are more susceptible to MRSA skin infection, infected diabetic mice exhibit enhanced neutrophil and macrophage recruitment in late phases of infection, infected skin from diabetic mice produces overwhelming production of LTB4 and BLT1 expression and inhibition of LTB4 actions improves animal abscess and microbial clearance.

[SEE SLIDES FROM DR. SEREZANI'S PRESENTATION](#)



Keynote Address

CAR T: From Model T to Sports CARs

Their keynote address was given by Carl H. June, M.D., recipient of the 2015 Watanabe Prize in Translational Research, Richard W. Vague Professor of Immunotherapy and Director of the Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania.

In his address, Dr. June presents the data, evidence and findings of his work and trials with CARs and TCRs as an immunotherapy treatment for cancer in children and adults. Download the slides to see his full presentation, in which he outlines his work and

results.

Are You an Investigator Needing Help?

About

News & Events

Research Resources

Training & Education

Grants & Funding

Community Engagement

Volunteer for Research

Tools

Triggering ST2 on T9 Cells as a Cure for Acute Myeloid Leukemia

Sophie Paczesny, M.D., Ph.D.
Associate Professor
Indiana University School of Medicine

Sophie Paczesny, M.D., Ph.D. presents the evidence and data to demonstrate the effectiveness of ST2 and T9 cell triggering to cure acute myeloid leukemia.

[SEE SLIDES FROM DR. PACZESNY'S PRESENTATION](#)

Immunotherapy of Cancer

Michael Kalos, Ph.D.
Chief Scientific Officer, Cancer Immunobiology
Lilly Research Laboratories
Eli Lilly and Company

In his presentation, Michael Kalos, Ph.D., explains the latest updates, evidence and information for the effectiveness of immunotherapy in treating cancer -- and how this could change the treatment field in the near future.

[SEE SLIDES FROM DR. KALOS'S PRESENTATION](#)



New Findings in Bone Marrow and Cord Blood Transplantation

Hal E. Broxmeyer, Ph.D.
Professor of Microbiology/Immunobiology
Indiana University School of Medicine

Hal Broxmeyer, Ph.D., presents compelling evidence and data to support the idea that knowledge and consequences of extra-physiologic oxygen shock/stress (EPOSS) will have widespread ramifications for studies and interpretation of cell metabolism and function in many stem/mature cell systems. Through his study with EPOSS, Broxmeyer and his team suggest that any cells

collected and processed in air may not reflect their true functional state, as opposed to what could occur in their vivo hypoxic environment. This could be of paramount importance when considering personalized medicine.

Commercializing Gene and Cell Therapy Programs

Erik Woods, Ph.D.
Senior Vice President
Cook Regentec

In his presentation on the commercialization of gene and cell therapy programs, Erik Woods, Ph.D., discusses the intersection of gene and cell therapies, industry infrastructure needs, challenges facing commercialization, the current gene and cell therapy commercialization status and challenges facing entrepreneurs in the industry.

Panel Discussion: What is the Patient's Perspective?

Moderated by Jose Azar, M.D., assistant professor of clinical medicine, hematology/oncology, Indiana University School of Medicine. The panel included two patients and the mother of a patient. They shared their experiences with treatment and clinical trials and provided a patient's outlook and perspective on how technology is shaping the future of cancer treatment. Video of the panel discussion is available at the link provided above.

Save the Date: The 8th Annual Meeting is Friday, Sept. 23.



[Support & Feedback](#)

[Citing CTSI](#)

[Newsletter](#)

[Grants Login](#)

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [IUPUI](#); concept by [Tufts CTSI](#).
Copyright © 2014 Indiana CTSI

Contact:
info@indianactsi.org

[News Center](#)
[Newsletter](#)
[Announcements](#)
[Meetings](#)
[Archives](#)
[Contact](#)

Polycystic kidney disease treatment enters clinical trial phase

A study on the treatment of polycystic kidney disease, initially funded by the Indiana Clinical and Translational Sciences Institute, has gained new momentum and is now entering the clinical trial phase under the guidance of a team of [Indiana University School of Medicine](#) researchers and a colleague at the Mayo Clinic.

[Polycystic kidney disease](#) affects more than 1 in 1,000 Americans, causing cysts to form on the kidneys. The cysts cause the kidneys to enlarge — sometimes becoming as big as footballs — leading eventually to kidney failure.

Under a three-year, \$600,000 Food and Drug Administration grant, Bonnie Blazer-Yost, Ph.D., and Sharon Moe, M.D., will serve as co-principal investigators into whether pioglitazone, also known as Actos, is an effective long-term therapy to stop autosomal dominant polycystic kidney disease.

While healthy adult kidneys are the size of a fist and weigh less than a pound, polycystic kidneys can weigh as much as 20 to 30 pounds. The fluid-filled cysts initially grow out of nephrons, tiny filtering units within the kidney, but eventually separate from the nephrons and continue their growth while the kidney enlarges as well.

“At present, there are no FDA-approved drugs to treat PKD and the only therapies are to either aspirate the larger cysts to relieve the pain or perform a transplant once the kidney fails,” Blazer-Yost said, “What we hope to demonstrate is the ability to halt or greatly inhibit cystic growth in our trial participants. If this proves successful, it will lead to larger trials with the ultimate goal of having a treatment for PKD that can be used as a lifelong medication.”

Blazer-Yost is a biology professor at Indiana University-Purdue University Indianapolis, while Moe serves as a professor and chief of nephrology at the Indiana University School of Medicine. Robert Bacallao, M.D., an associate professor of medicine and director of the Polycystic Kidney Disease Clinic at the IU School of Medicine, also will serve as a co-investigator. Vicente Torres, M.D., Ph.D., a professor of medicine at the Mayo Clinic’s Division of Nephrology and Hypertension in Rochester, Minn., will consult and provide magnetic resonance imaging interpretation for the study.

Blazer-Yost’s work with PKD originated in diabetes research. Shortly after arriving at IUPUI in 1993, she worked with GlaxoSmithKline to determine why rosiglitazone, a Type 2 diabetes drug also known as Avandia, caused fluid retention. Her findings revealed that the drug affected a different electrolyte channel, one involving chloride, than the drug company expected.


“As it turned out, this was the same chloride channel involved in cyst growth in PKD,” Blazer-Yost said, “In PKD, the chloride channel causes chloride secretion into the cysts, water follows and the cysts enlarge.”

From there, Blazer-Yost and the late [Vincent Gattone, M.D.](#), an IU School of Medicine professor of anatomy and cell biology who died of cancer in 2014, used animal models to study how rosiglitazone and the similar compound pioglitazone may be useful in treating PKD. The Indiana CTSI funded the initial collaboration between Blazer-Yost and Gattone, first testing the drugs at standard, high dose. The drug slowed cyst growth.

Next came experiments to test the drugs’ effectiveness at the lower doses. The low dose regimens also were effective. Finally Blazer-Yost and Gattone tested the drug at concentrations below those used to treat insulin. As suggested by the tissue culture studies, these very low concentrations of both Actos and Avandia were effective. These findings showed that both drugs not only delayed PKD cyst growth in rats, but did so in concentrations 10 times smaller than doses used to treat diabetes. The low-dose effectiveness tests were also funded by the Indiana CTSI. Total Indiana CTSI support for Blazer-Yost and her collaborators has been nearly \$75,000, including two grant from the [Indiana CTSI Project Development Team Program](#) as well as a [Core Pilot Fund Grant](#) for use of the [IU Electron Microscopy Center](#).

Though Blazer-Yost was unsure that human trials would see funding due to the cloud that hangs over the drugs, she and her team of collaborators are beginning patient recruitment this month, with 28 subjects envisioned for the study’s first two phases. Blazer-Yost credits the Indiana CTSI for making it possible to even apply for clinical trial funding.

Learn more about the [history of Blazer-Yost’s work](#), or contact Kristen Ponsler-Sipes at kmponsle@iu.edu, to volunteer for the trial.



Are You an Investigator Needing Help?

About

News & Events

Research Resources

Training & Education

Grants & Funding

Community Engagement

Volunteer for Research

Tools

Support & Feedback

Citing CTSI

Newsletter

Grants Login

This website is supported by Indiana and Purdue universities. Design by IUPUI, concept by Tufts CTSI. Copyright © 2014 Indiana CTSI

Contact:
info@indianactsi.org

[News Center](#)
[Newsletter ▼](#)
[Announcements ▼](#)
[Meetings ▼](#)
[Archives ▼](#)
[Contact](#)

NIH five-year grant funds new diabetes research center and related cores

The National Institutes of Health has awarded the Indiana University School of Medicine a **five-year, \$4.5 million grant** to create a new federally designated Indiana Diabetes Research Center, one of just 16 such centers in the country.

The new IU Center for Diabetes and Metabolic Diseases, directed by Raghu G. Mirmira, M.D., Ph.D., Eli Lilly and Company Professor of Pediatric Diabetes and its associate director Robert V. Considine, Ph.D., professor of medicine and of cellular and integrative physiology, was made possible, in part, by seed funding from a CTSI Program Project Planning (P3) PDT award.

The grant will accelerate and expand diabetes and metabolic research programs across the campus, along with several research cores providing specialty research functions.

- **A Microscopy Core**, headed by Kenneth W. Dunn, Ph.D., professor of medicine and scientific director of the Indiana Center for Biological Microscopy, will provide microscopy imaging services.
- **An Islet Core**, headed by Carmella Evans-Molina, M.D., Ph.D., associate professor of medicine, will provide services related to the research usage of islets, the pancreatic clusters of cells that produce insulin.
- **A Swine Core**, headed by Michael Sturek, Ph.D., professor of cellular and integrative physiology, will accelerate understanding of physiological principles of diabetes and metabolism by studying novel models in swine.
- **A Translation Core**, headed by Kieren J. Mather, M.D., professor of medicine, focusing on translating basic laboratory science discoveries into a better understanding of disease in humans.
- **A Pilot & Feasibility Core**, part of the Enrichment Program, headed by Jeffrey S. Elmendorf, Ph.D., associate professor of cellular and integrative physiology, will award up to four \$45,000 pilot research grants annually to young researchers.



Visit the [Indiana Diabetes Research Center website](#) to learn more about each core.

[Support & Feedback](#)
[Citing CTSI](#)
[Newsletter](#)
[Grants Login](#)

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [IUPUI](#); concept by [Tufts CTSI](#).
 Copyright © 2014 Indiana CTSI

Contact:
info@indianactsi.org

Are You an Investigator Needing Help?

- News Center
- Newsletter**
- Announcements
- Meetings
- Archives
- Contact

- About
- News & Events
- Research Resources
- Training & Education
- Grants & Funding
- Community Engagement
- Volunteer for Research
- Tools

GLUE Grants awarded to inspire cross-campus collaboration

The Indiana Clinical and Translational Sciences Institute recently selected three projects to receive \$200,000 each in funding for the next two years through the IU Grant Linking University-Wide Expertise (GLUE) Awards. The three projects address issues in psychological and brain sciences, and chemistry.

Ken Mackie, M.D., professor of psychological and brain sciences at Indiana University Bloomington is the principal investigator for the Translational Adolescent Cannabis Use Research Center. The goal of this center, after funding from the National Institutes of Health, is to investigate the antecedents and effects of adolescent cannabis use in both preclinical models and in adolescent and young adult populations, as well as to develop novel, evidence-based therapies. Its accomplishments will both contribute to the public policy debate on cannabis and help devise more effective therapeutic strategies. Co-investigators include Stephen Boehm, Ph.D., of IUPUI, and Karmen Yoder, Ph.D., of the IU School of Medicine.

Franco Pestilli, Ph.D., assistant professor of psychological and brain sciences, was awarded funds for his project titled, "Improved Accuracy for Anatomical Mapping and Network Structure of the Alzheimer's Brain." The purpose of the study is to investigate the structure of the human brain connectome in individual brains to build predictive models of prodromal Alzheimer's disease, with the goal of informing precision medicine. Co-investigators on this project include Andrew Saykin, Psy.D., Joaquin Goni, Ph.D., and Li Shen, Ph.D., of the IU School of Medicine, and Olaf Sporns, Ph.D., of the Department of Psychological and Brain Sciences.

Peter Ortoleva, distinguished professor in physical chemistry and chemical biology at IU Bloomington will conduct a study titled, "Integrated Computational and Laboratory Approach for the Efficient Discovery of Antiviral Vaccines." Through this study, an integrated program of computational and experimental methods will be developed to facilitate the discovery of vaccines that protect against viral infections. Co-investigators include Aaron Ermel, M.D., and Darron Brown, M.D., of the IU School of Medicine.

About the GLUE Awards

The mission of the GLUE awards is to support cross-campus planning and team building with the goal of developing multi-investigator and/or multi-project, milestone-driven translational research teams who eventually plan to submit a multi-year extramural grant. These planning/seed grants increase multidisciplinary collaborations, institutional competitiveness, opportunities for extramurally funded training grants and overall institutional funding.



- Support & Feedback
- Citing CTSI
- Newsletter
- Grants Login

This website is supported by Indiana and Purdue universities. Design by IUPUI; concept by Tufts CTSI. Copyright © 2014 Indiana CTSI

Contact: info@indianactsi.org

Are You an Investigator Needing Help?

- News Center
- Newsletter** ▾
- Announcements ▾
- Meetings ▾
- Archives ▾
- Contact

- About ▾
- News & Events ▾
- Research Resources ▾
- Training & Education ▾
- Grants & Funding ▾
- Community Engagement ▾
- Volunteer for Research ▾
- Tools ▾

BioStorage & CTSI develop technology for medical researchers

BioStorage Technologies recently partnered with the Indiana University School of Medicine, Susan G. Komen Tissue Bank and Indiana Clinical and Translational Sciences Institute to develop technology that will enhance sample utilization and optimization by researchers.

An industry pioneer of comprehensive sample management, this partnership leverages **BioStorage's ISIDOR® technology solution**, a transformational and scalable informatics platform which integrates research and sample data to advance bioscience discoveries. ISIDOR consolidates and integrates research samples and data for improved visibility and access to samples in storage. This technology also connects relevant data to these samples, and ultimately advances medical research.

"We identified synergies to innovate with a fellow Indiana-based life sciences organization, BioStorage Technologies, and create an environment where sample assets and data sharing across the enterprise will enhance opportunities to support and fast-track future research endeavors," said Anantha Shekhar, M.D., Ph.D., executive associate dean for research affairs, IUSM and director, Indiana CTSI.

BioStorage Technologies and **IU Health** are now also in discussions regarding the next steps in advancing the project. The utilization of the ISIDOR technology solutions platform at IU Health allows for greater sharing and optimization of research samples and associated data across the enterprise.

IU Health's focus is on evaluating opportunities for leveraging the integration of sample and research data. In addition, this project is generating internal efficiencies in the management of research samples, enabling improved data sharing and paving the possibility for the development of an online marketplace for the sharing and cost-recovery of research samples.

"Partnerships with industry are a key to the leading edge research," said IU Health CEO, Dan Evans. "IU Health and the IU School of Medicine seek to collaborate with industry to innovate. Technology accelerates progress in diverse ways, and we seek technology partnerships to enable the delivery of the best care."

"It was a pleasure to partner with these leading US medical research institutions," said Lori Ball, COO and president, Integrated Solutions, BioStorage Technologies. "Together, we implemented an agile, advanced technology solutions architecture into a complex environment which demonstrates the ability for ISIDOR to deliver a flexible and personalized approach to integrating data virtualization with intelligent data visualization. This consolidated view of harmonized data showcases the leadership and dedication of the IU Health organization in advancing scientific research."



BioStorage
TECHNOLOGIES

Support & Feedback

Citing CTSI

Newsletter

Grants Login

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [IUPUI](#); concept by [Tufts CTSI](#). Copyright © 2014 Indiana CTSI

Contact: info@indianactsi.org

[News Center](#)
[Newsletter ▼](#)
[Announcements ▼](#)
[Meetings ▼](#)
[Archives ▼](#)
[Contact](#)

Indiana Center for Biological Microscopy introduces new functionalities

The Indiana Center for Biological Microscopy will offer new functionalities in high-resolution imaging for large-scale 3D studies, simultaneous detection of multiple cytokines and Ultrasensitive Cira Assays.

Seth Winfree, microscopy technologist with the [Indiana University School of Medicine's Indiana Center for Biological Microscopy](#), recently built a Selective Plane Illumination Microscope system. This high resolution microscopy system is ideally suited for imaging large-scale structures like embryos, organoids and 3D tissue culture models. Investigators interested in using the system should contact Winfree at winfrees@iu.edu.



With the acquisition of new objective lenses, the Leica SP8 confocal/multiphoton system is now capable of collecting 4-color images at the rate of 30 to 200 frames per second at any magnification, significantly boosting the efficiency of large-scale 3D imaging studies.

Center for Biological Microscopy personnel have received final training in the use of the new Imaris 3D image analysis software, a powerful tool for quantitative analysis and exploration of 3D microscopy data. Investigators interested in learning about the Imaris software should contact Gosia Kamocka at mkamocka@iu.edu.

The BioPlex Biomarker Core has received a new Aushon Ciraplex. This multiplex platform technology is capable of simultaneous detection of multiple cytokines and offers Ultrasensitive Cira Assays, which can detect femtogram/mL levels of protein. Arrays are available for human, mouse, porcine, bovine, primate and rat. Contact Dr. Christie Orschell for more information at orschel@iu.edu.

These new offerings were made possible through funding from the IUPUI Imaging Technology Development Program, Indiana CTSI, and IU School of Medicine Division of Nephrology and the IU Simon Cancer Center.

Are You an
Investigator
Needing Help?

About ▼

News & Events ▼

Research Resources ▼

Training & Education ▼

Grants & Funding ▼

Community Engagement ▼

Volunteer for Research ▼

Tools ▼

Support & Feedback

Citing CTSI

Newsletter

Grants Login

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [IUPUI](#); concept by [Tufts CTSI](#). Copyright © 2014 Indiana CTSI

Contact:
info@indianactsi.org

Are You an
Investigator
Needing Help?

- About ▼
- News & Events ▼
- Research Resources ▼
- Training & Education ▼
- Grants & Funding ▲
 - All CTSI Funding
 - All Open RFPs
 - Other Funding
 - Grant Management
 - Citation Information
 - No Cost Extensions
- Community Engagement ▼
- Volunteer for Research ▼
- Tools ▼

All Open Indiana CTSI Request for Proposals

This page lists all Indiana CTSI funded proposals currently accepting applications. You can click on the grant title for further details for that grant. The "START" link at the bottom of each grant will take you to the CTSI grants system (which requires login) and start the application process.

Infectious Diseases T32 Training Program- 2017.03

APPLICATION SUBMISSION DEADLINE - MARCH 07, 2017

This training opportunity is a collaborative effort between the Division of Infectious Diseases (ID), Department of Medicine; the Sections of Adolescent Medicine and Infectious Disease & Global Health, Department of Pediatrics; the Department of Dermatology and; the Department of Microbiology and Immunology.

The primary mission of this multidisciplinary training program is to train well qualified MD and PhD scientists for productive and sustainable careers in research. The scope of training ranges from bench science to implementation research. In addition, as team science is rapidly becoming the primary mode of operation for biomedical scientists addressing complex questions related to human health, this opportunity emphasizes training investigators who are familiar with the practices, procedures, and languages of collaboration necessary for creating and working within a productive team. This opportunity uses a broad based integrative approach, supported by excellent mentors, in order to achieve the goal of training superb researchers for the next generation.

IIMR VA Young Investigator Award (YIA) - 2017.02

LETTER OF INTENT (LOI) DEADLINE JANUARY 18, 2017

APPLICATION SUBMISSION DEADLINE - FEBRUARY 08, 2017

IIMR's mission is to promote and enhance research efforts that will ultimately result in improved quality of life for veterans and for the greater population. In support of that mission, IIMR works to encourage investigators to develop their research careers by working with IIMR and the VA and veterans to answer important questions. One way IIMR encourages investigators is to sponsor the annual Young Investigator Award Program, which provides a competitive experience for investigators to explore the possibilities of VA-related research.

The IIMR is currently seeking submissions for clinical, basic science and translational research. It is expected that two meritorious awards will be funded through this RFA cycle. Project budgets should be limited to those funds necessary to carry out the research project and should be limited to \$25,000.

Please note: If you want to attend a grants writing workshop or educational session prior to completing your YIA submission, please contact the IIMR via Mary.Gray1@va.gov, 317.988.9544, or refer to the IIMR website at iimrindy.org. Our office will be happy to assist you in enrolling in a workshop or session.

MD/MS Fellowship Program: Year in Translational Research for Medical Students - 2017.03

SUBMISSION DEADLINE - MARCH 07, 2017 (4:00 PM)

The Indiana Clinical and Translational Research Institute (CTSI) is seeking applicants for a special research fellowship in translational research. This fellowship program will be awarded through a competitive process. CTSI will provide an annual stipend and one year of health insurance coverage for as many as two IUSM medical students interested in taking a year out of medical school to pursue an M.S. in Translational Science.

CTSI - IU Kelley MBA Core and Project Business Management Assistance - 2017.01

SUBMISSION DEADLINE – JANUARY 16, 2017 (5:00 PM)

The Indiana CTSI, jointly with the IU Kelley School of Business, offers to provide for a team of 2-5 Indiana Kelley MBA students (from the residential-MBA program in Bloomington) to be your partners for the project as a part of their independent study program for course credit. Project duration will be 8 weeks. Selected cores will be expected to engage with the MBA students for initial project scope (2 hours), additional follow-up or onsite meetings (8-12 hours) and a final project close-out (1-2 hours). The MBA students will contribute 30-100 hours each (depending on the project scope, number of team members and course credit assignment) to the project progression in turn. **Selected projects will commence in February - March 2017 and will be completed by early May.**

CTSI Young Investigator Award in Clinical - Translational Research - 2017.01

SUBMISSION DEADLINE - JANUARY 17, 2017 (5:00 PM).

The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for the CTSI Young Investigator Awards in Clinical-Translational Research. These awards are designed to provide promising junior investigator faculty with the opportunity to be mentored in research-intensive multi-disciplinary settings toward the goal of developing careers in clinical-translational research. Clinical research includes epidemiological studies, clinical trials, or other investigations involving human subjects. Translational research consists of either "T1 research"

(interface of basic science to human studies) or "T2 research" (interface of human studies to the community). To be eligible, candidates must fall into 1 of the following 2 categories: 1) Clinician-scientists with a doctoral degree (physicians, nurses, dentists, pharmacists, clinical psychologists, optometrists, veterinarians, allied health care professionals, etc.) or 2) Basic scientists with a PhD who are doing translational research, which involves some component of human subjects research and has high potential for early translation in impacting patient care.

CTSI Postdoctoral Training Awards in Translational Research - 2017.01

SUBMISSION DEADLINE - January 13, 2017 (5:00 PM). The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices, or both. To be eligible, candidates must have received a PhD or equivalent degree from an accredited domestic or foreign institution. Please refer to the competition guidelines for full eligibility criteria.

Ralph W. and Grace M. Showalter Research Trust - 2017.01

KC ROUTING DEADLINE - January 10, 2017 (5:00 PM).

Since 1975, IUSM has received research funding through gifts made possible from the Ralph W. and Grace M. Showalter Research Trust Fund. The areas of appropriate biomedical research, eligible for funding, are broad and described by the benefactors as "the type of medical research that is most likely to permanently benefit mankind." Donor intent prohibits the use of Showalter Trust funds for research in psychiatry, sociology, or social studies. Applications for funding from the Ralph W. and Grace M. Showalter Research Trust will be reviewed in two stages. An initial review by the IUSM Biomedical Research Committee (BRC) will select the most meritorious proposals for further discussion and ranking. The BRC will then provide a recommended ranking to the Showalter Trustees who conduct a second review. Final funding decisions are made by the Showalter Trustees. Applications for funding beginning July 1, 2017 must be routed to the Office of Research Administration (ORA) by 5pm on Tuesday, January 10. ORA approved applications should then be uploaded to the CTSI website no later than 5:00 pm Tuesday, January 17. Only current full-time faculty (non-visiting status) having a primary appointment in IUSM and a rank of assistant professor or assistant scientist are eligible to apply for funding from the Showalter Research Trust. Note that the same proposal may not be submitted as both a Biomedical Research Grant and a Showalter Trust application. If eligible for both programs, the investigator is encouraged to submit to the Showalter Trust.

Biomedical Research Grant - 2017.01

SUBMISSION DEADLINE - January 10, 2017 (5:00 PM).

The Biomedical Research Grant program is open to all IU School of Medicine (IUSM) faculty that are full-time, regardless of tenure status, having an appointment of Assistant/Associate/Full Professor and Assistant/Associate/Full Scientist. In general, two categories of research projects will benefit from this program: 1) research projects of investigators new to IUSM who do not yet have extramural funding and who need support to acquire the preliminary data necessary to compete for extramural funding; 2) research projects of established IUSM investigators who are between funding periods from extramural sources.

Design and Biostatistics Program (DBP) Pilot Grant - 2017.02

LETTER OF INTENT (LOI) DEADLINE - DECEMBER 16, 2016

FULL APPLICATION DEADLINE - FEBRUARY 6, 2017 (5:00 PM)

The Design and Biostatistics Program (DBP) of the Indiana Clinical and Translational Science Institute (CTSI) is comprised of 8 units with associated expertise: 1) Department of Biostatistics, IU School of Medicine and Fairbanks School of Public Health; 2) Division of Hereditary Genomics, Department of Medical & Molecular Genetics, IU School of Medicine; 3) Computational Biology, Center for Computational Biology & Bioinformatics, IU School of Medicine; 4) Department of Epidemiology, Fairbanks School of Public Health; 5) Department of Statistics, Purdue College of Science; 6) Department of Applied & Computational Math & Statistics, Notre Dame School of Science; 7) Department of Statistics, IU Bloomington College of Arts & Sciences; 8) Department of Epidemiology and Biostatistics, IU Bloomington School of Public Health.

To achieve its objectives and stimulate development for emerging translational research needs, the DBP will fund innovative pilot projects that support methodological research of faculty members in the eight units that comprise the DBP. The total budget for the entire RFA is \$20,000, and it is expected that up to two awards will be funded at approximately \$10,000 per award for a twelve month duration. The objective of this mechanism is to fund research proposals that will synergize methodological strengths and translational biomedical research of the DBP, and in particular, the following types of research proposals:

- Research projects that propose to develop novel methodology (such as biostatistical, epidemiological, genetic, and bioinformatics methods).
- Research projects that match novel methodology with translational science needs.
- Research projects that have high potential to obtain external funding.

Preference will be given to investigators who have not already received extramural funding. Applications to this program are expected to be **\$10,000 per award** and are of **one (1) year duration**.

START

CTSI Pre-Doctoral Training in Translational Research - 2016.12

CV SUBMISSION PRIOR TO APPLICATION (via ictsi@purdue.edu) DEADLINE - DECEMBER 5, 2016

FULL APPLICATION DEADLINE - DECEMBER 12, 2016 (4:00 PM)

The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special predoctoral training awards in translational research. In biomedical terminology translational research refers to what is popularly termed "bench to bedside", the process by which research in the lab "translates" into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of

best practices, or both. These two types of translational research are usually described as consisting of either "T1 research" (basic biomedical research, e.g. study disease at a molecular or cellular level, as it progresses to the development of new treatment options at the clinical level) or "T2 research" (enhancing access to and the adoption of evidence-based strategies in clinical and community practice, institutionalizing programs, products, and services to improve health). These awards are aimed at predoctoral students whose research is at any point along this spectrum. **Funding is for two years (with the 2nd year of funding contingent upon satisfactory progress).** Benefits include a stipend as well as health insurance and partial coverage of tuition and fees.

Center for Diabetes and Metabolic Diseases' Pilot and Feasibility - 2017.03

LETTER OF INTENT (LOI) DEADLINE - JANUARY 9, 2017 (5:00 PM)

FULL APPLICATION DEADLINE - MARCH 6, 2017 (5:00 PM)

This funding opportunity announcement invites applications from investigators at Indiana University (IUSM, IUB, etc.), IUPUI, and Purdue. The program will be particularly directed at new investigators and established investigators new to diabetes-related research. The program will also consider established diabetes investigators pursuing high impact/high risk projects or projects that are a significant departure from their usual work. The campuses are ideal for establishing interdisciplinary collaborations and forging new partnerships between basic scientists and clinical researchers, and such collaborations are encouraged. Work supported by these funds is expected to lead to submissions of major extramural grants (R01/equivalent NIH, major foundation awards, DOD, etc.).

START

Global Health Research Pilot Projects -2016.12

SUBMISSION DEADLINE – DECEMBER 12, 2016 (5:00 PM)

The Indiana CTSI with the IU Center for Global Health is soliciting proposals from applicants developing or currently involved in collaborative global health research projects. The purpose of this RFA is to foster and encourage the development of new collaborative interdisciplinary research that seeks to identify innovations to address key global health challenges and improve health outcomes in resource limited settings. This RFA will fund pilot research projects with: (1) a high potential for attracting new extramural research funding; (2) a focus on strengthening collaborative multidisciplinary research collaborations between Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and key academic research centers abroad; and (3) an emphasis in key, high-yield, research-related initiatives, including basic and translational sciences research, biobanking, cancer, population focused disease control, informatics and decision support systems, and implementation research dissemination.

Post-Doc Challenge - Funding to Utilize CTSI-Designated Cores - 2017.02

FULL APPLICATION DEADLINE - TUESDAY, FEBRUARY 28, 2017 (5:00 PM)

The Indiana Clinical and Translational Sciences Institute (CTSI) is soliciting proposals from postdoctoral researchers to develop translational research through the use of technologies and expertise available at the Indiana CTSI-designated core facilities available at all partner institutions. Translational research refers research in the lab that eventually translates into patient treatment to improve human healthcare. Translation involves applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans.

CTSI-designated core facilities are cores that undergo a yearly accreditation process through the Indiana CTSI for all partner institutions. The Postdoc Challenge offers postdoctoral researchers at Indiana University, Indiana University School of Medicine, IUPUI, Purdue University, and the University of Notre Dame valuable proposal writing and reviewing experience in areas related to translational research through the use of one or more of the CTSI-designated core facilities at any of the partner universities. This is a competitive opportunity for a \$5,000 award in the form of an expense account for use of core facility services. Funding is to be used only for services provided by the core facilities. Indiana CTSI-designated core facilities are listed on the CTSI HUB. (<https://www.indianactsi.org/servicecores>)

Applications to this program are **limited to \$5,000** and are of **one (1) year duration**.

START

Adult Gastrointestinal and Liver Diseases Research Pilot Grant - 2016.11

LETTER OF INTENT (LOI) DEADLINE - FRIDAY, OCTOBER 21, 2016

FULL APPLICATION DEADLINE - MONDAY, NOVEMBER 7, 2016 (5:00 PM)

The Indiana Clinical and Translational Sciences Institute (CTSI), in conjunction with the Division of Gastroenterology/Hepatology in the Department of Medicine, is soliciting proposals for pilot projects from investigators to develop and promote translational and transdisciplinary collaborative research projects in adult gastrointestinal and liver diseases. The objective is to fund studies that (a) establish or strengthen already established collaborations between faculty members in the GI Division and investigators from other departments and schools at IUSM, IUPUI and Purdue University; (b) generate preliminary data for extramural funding applications investigating adult GI and liver disorders.

The areas of interest include (a) acute and chronic liver diseases; (b) GI and hepatobiliary malignancy; (c) inflammatory bowel disease; (d) GI motility disorders; (e) chronic abdominal pain; and (f) chronic functional bowel disorders. The proposal should demonstrate tangible evidence that the collaboration will lead to a multiyear federal grant application.

Applications to this program are **limited to \$35,000** and are of **one (1) year duration**. Up to two grants will be awarded per grant cycle.

Indiana Spinal Cord & Traumatic Brain Injury Research Fund - 2016.12

FULL APPLICATION DEADLINE - FRIDAY, DECEMBER 9, 2016 (5:00 PM)

The overall objective of the Indiana Spinal Cord & Traumatic Brain Injury Research Fund program is to foster and encourage research for the prevention, treatment and cure of spinal cord and traumatic brain injuries, including acute management, medical complications, rehabilitative techniques, and neuronal recovery. Collaborations are encouraged between Indiana-based researchers as well as with researchers located outside the state of Indiana, including researchers in other countries. Even though the Indiana statute encourages collaborations with

researchers outside of Indiana, the primary research should be Indiana-based. Collaborations can be between Principal Investigators (PIs) at the same institution, different institutions, or a PI and a company. Salary support for collaborators outside of Indiana will be limited.

Applications to this program are **limited to \$160,000** and are of a **two (2) year duration**, with a \$80,000 per year maximum.

Pilot Funding For Research Use of Core Facilities - 2016.10

FULL APPLICATION DEADLINE - FRIDAY, OCTOBER 7, 2016 (5:00 PM)

The Indiana CTSI Pilot Funding program is intended to promote the use of technologies and expertise afforded by the Indiana CTSI Core Facilities available at all partner institutions. Successful proposals will demonstrate outstanding scientific merit that can be linked to generating extramural funding or novel intellectual property (IP). Success of the program will be viewed, in part, by the fostering of new funded grants or providing significant contributions to grant renewals. Therefore, proposals will be judged with equal measure on scientific merit and the likelihood of generating new IP or extramural grant support.

Indiana University Health Values Fund: Pilot and Feasibility Education Program - 2016.11

FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)

Indiana University Health's strength in providing excellent patient care is partially based on involvement in the continuous development of new, pre-eminent health care professionals throughout the entire workforce and innovative care delivery models. The Indiana University Health is seeking applicants for the IUH Pilot and Feasibility Education Program. The specific areas of opportunity of the program include the following: 1) Educational efforts in the field of ethics involving students, residents, or staffs; 2) Support for translation or dispersal of knowledge (e.g. library); 3) Education in Health Evaluation and Services, including outcomes evaluation and procedures; 4) Educational efforts especially with residents and staff which address ethical, socioeconomic, medical, legal and cost containment, or other issues affecting medical practice, quality of life, and access to health care; 5) Educational efforts in an ambulatory setting and/or promotion of continuity of care across care settings; 6) Education involving alternate approaches to health care including spirituality, end of life care, etc., or educational efforts which attempt to integrate complementary and traditional medicine in support of providing holistic care; 7) Educational efforts involving delivery of chronic care; 8) Primary care education devoted to holistic care; 9) Education in research principles; 10) Education in the development of and delivery of health promotion projects; 11) Educational efforts in faculty, resident, professional and/or staff development as related to teacher/learner issues; and 12) Education in quality improvement.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

Indiana University Health Values Fund: Pilot and Feasibility Research Program - 2016.11

LETTER OF INTENT (LOI) DEADLINE - OCTOBER 21, 2016

FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)

Indiana University Health is seeking applicants for the IUH Pilot and Feasibility Research Program. The priority areas of the program include the following areas: 1. Discovery of new knowledge and the development of new diagnostic treatment and prevention modalities to improve patient care outcomes; 2. Promotion of health in the population and the provision of health care of the highest quality to its patients while assisting the hospital to become more efficient; 3. Projects that demonstrates collaboration between the Indiana University Health hospital campuses.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

Indiana University Health Values Fund: Grand Challenge Grant - 2016.11

LETTER OF INTENT (LOI) DEADLINE - OCTOBER 21, 2016

FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)

This is a relatively new component of the IU Health Values Fund Grant Program. Values Fund expenditures represent an expression of Indiana University Health's seven Core Values. The Grand Challenge is funded in support of the Indiana University Health values. The proposed "Grand Challenge" Values grants will compliment Indiana University Health's strength in providing excellent patient care and health education by adding a new dimension this award round by addressing '*smoking cessation studies as well as projects focusing on behavioral health*'. This new focus further aligns IU Health with the State of Indiana's strategies to combat smoking and behavioral health. Thus, the IU Health Grand Challenge (IUH GC) applications are expected to make a significant impact on key communities served by IU Health and demonstrate how the awards will improve the health outcomes of targeted communities in Indiana and beyond. Grand Challenge proposals will be accepted that focus specifically on population health research on any of the following two topics: 1) Reduce tobacco use and/or exposure to secondhand smoke that scales across the health system, strengthens community partnerships, and advances public health impact of IUH/IUSM; 2) Develop a model of care and necessary workforce to address serious behavioral health problems that can be deployed across the health system and advances IUH/IUSM's public health impact and community partnerships.

Applications to this program are **limited to \$500,000** and are of **two (2) year duration**, with a \$250,000 per year maximum.

Indiana University Health Values Fund: Integration of Spiritual and Religious Dimensions in Health Care - 2016.11

LETTER OF INTENT (LOI) DEADLINE - OCTOBER 14, 2016 (5:00 PM)

FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)

IU Health's strength in providing excellent patient care is rooted in the religious and spiritual heritage of its institutions. The spiritual calling to heal the sick brings vitality and meaning to patient care within the IU Health community. The Joint Commission on Accreditation has emphasized spiritual care as a vital part of the mission of health care institutions. IU Health will succeed in meeting its mission to provide holistic care to our patients with new programs to integrate spiritual care into patients' treatment plans and to develop methods and find solutions to address all the needs of those we serve. The Values Fund offers a unique resource that will allow us fulfill our mission and uphold our values.

Indiana University Health is seeking applicants for the Indiana University Health Values Fund for the Integration of Spiritual and Religious

Dimensions in Health Care. The specific areas of opportunity of the program include the following: 1) Projects that seek to foster a "whole person perspective" in health care; 2) Projects that foster policies and procedures that enhance respect for patient rights and responsibilities; 3) Projects that coordinate and provide a forum and consultation in the area of religious and moral meaning in bioethics; 4) Projects that research the role of religion, spirituality, and/or ethics in health and healing; 5) Projects that provide a service as a religious and ethical values resource center within the IU Health network and the broader community; 6) Projects that support innovation in spiritually integrated counseling, particularly for low income persons and families; and 7) Projects that provide a linkage with, and liaison between, the religious community and IU Health, addressing the continuum of care and wellness issues in our society.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

IU School of Medicine/Purdue University - Devices Advancing Surgical Care - 2016.10

SUBMISSION DEADLINE - OCTOBER 31, 2016 (5:00 PM).

The Indiana Clinical and Translational Sciences Institute (CTSI) is please to request applications for funding to develop potential devices in the broad area of surgery. The successful application will involve investigators from the Department of Surgery at Indiana University School of Medicine and faculty from Purdue University. Awards will be competitive and may not exceed \$100,000 for up to two (2) period. Investigators from both institutions are encouraged to come up with innovative ideas that can result in a device that improves human health. For questions regarding scope, review of the proposal, or financial issues related to budgeting and grant submission contact Lane Coffee at rlcoffee@iu.edu or via phone at 317-278-2150.

Dr. Charles Fisch Cardiovascular Research Award

PROPOSAL SUBMISSION DEADLINE - 1) FIRST REGULAR BUSINESS DAY IN APRIL and 2) FIRST REGULAR BUSINESS DAY IN SEPTEMBER (5:00 PM).

Indiana University School of Medicine announces the availability of Dr. Charles Fisch Cardiovascular Research Award to support cardiovascular research for young investigators or more senior investigators, embarking on a new research direction.

Applicants may request up to \$60,000 total, although particularly meritorious proposals that have well-justified budget needs as high as \$100,000 may be considered. Successful proposals will demonstrate scientific merit and a potential for generating extramural funding. In addition, prioritization will be given to those projects that utilize more than one IU Health hospital or facility for leveraging existing patient populations or clinical programs and/or projects that will potentially lead to improvements in the quality of care for IU Health patients. Applicants must have an Indiana University faculty appointment in the Department of Cardiology, Department of Medicine to apply for research program support. Clinical fellows and postdoctoral researchers in the Division of Cardiology may apply for research fellowship support under a faculty member in the Division of Cardiology.

START

Eli Lilly-Stark Neurosciences Pre-Doctoral Research Fellowship in Neurodegeneration - 2016.08

LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016

FULL APPLICATION DEADLINE - AUGUST 26, 2016 (5:00 PM)

The Stark Neurosciences Research Institute and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for special pre-doctoral training fellowships in translational neurodegenerative disease research. We seek applicants whose research is focused on age-related neurodegeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, among others. Translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translational research fosters the multidirectional integration of basic research, patient-oriented research, and population-based research, with the long-term aim of improving the health of the public. Translation can involve everything from basic science discoveries in the lab that directly focus on human disease states, through animal studies and drug development to the development of clinical trials and studies in humans.

Annual stipend (plus applicable health insurance) is aligned with current NIH recommendations. Annual supplement of \$7,500 to be used for travel, computers, and general supplies. Initial funding duration is for one (1) year, and is renewable for one (1) additional year pending review and demonstration of satisfactory progress.

Eli Lilly-Stark Neurosciences Post-Doctoral Research Fellowship in Neurodegeneration - 2016.08

LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016

FULL APPLICATION DEADLINE - AUGUST 26, 2016 (5:00 PM)

The Stark Neurosciences Research Institute and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for special post-doctoral training fellowships in translational neurodegenerative disease research. We seek applicants whose research is focused on age-related neurodegeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, among others. Translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translational research fosters the multidirectional integration of basic research, patient-oriented research, and population-based research, with the long-term aim of improving the health of the public. Translation can involve everything from basic science discoveries in the lab that directly focus on human disease states, through animal studies and drug development to the development of clinical trials and studies in humans.

Annual stipend (plus applicable health insurance) is aligned with current NIH recommendations. Annual supplement of \$7,500 to be used for travel, computers, and general supplies. Initial funding duration is for one (1) year, and is renewable for one (1) additional year pending review and demonstration of satisfactory progress.

Activity-Based Therapy Grant Program - Indiana Spinal Cord & Traumatic Brain Injury Research Fund - 2016.09

LETTER OF INTENT (LOI) DEADLINE - AUGUST 12, 2016

FULL APPLICATION DEADLINE - SEPTEMBER 9, 2016 (5:00 PM)

The State of Indiana established the research fund known as the Indiana Spinal Cord and Traumatic Brain Injury Research Fund (ISCBIRF) effective July 1, 2007. This fund, established under Indiana Code (IC) 16-41-42-4, will consist of appropriations, gifts and bequests, fees deposited in the fund under IC 9-29-5-2, and grants received from the federal government and private sources.

Effective July 1, 2015 this fund was supplemented and additionally authorized by legislation to provide prescribed, defined, and limited support to non-profit organizations corresponding to 501(c) 3 Federal tax status engaged in rehabilitative clinical care employing "activity based" approaches.

The overall objective of this program is to foster and encourage activity-based therapy programs for the prevention, treatment, and cure of spinal cord and traumatic brain injuries, including acute management, medical complications, rehabilitative techniques, and neuronal recovery.

Applications to this program are limited to \$1,000,000 (maximum of \$600,000 during the first year; \$400,000 during the second year) for up to two (2) years in duration based on appropriate achievement of milestones and progress reports.

IU Grant Linking University-wide Expertise (GLUE) Awards - 2016.09

LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016

FULL SUBMISSION DEADLINE - SEPTEMBER 2, 2016 (5:00 PM)

Indiana University, Bloomington, Provost's Office and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for the IU Grant Linking University-wide Expertise (GLUE) Award. The objective of the GLUE award is to support "planning and team building across campuses to develop large multi-investigator and/or multi-project, milestone-driven, translational research teams who are planning to submit multi-year, extramural grant applications with annual budgets of \$500K or more in direct costs." It is expected that these planning/seed grants will increase multidisciplinary collaborations, institutional competitiveness, opportunities for extramurally funded training grants and overall institutional funding. The GLUE funding is available to collaborative teams in which the lead PI of the research team is from IUB, and the other members of the team are typically from IU campuses such as IUPUI and IUSM (or in deserving cases, any other CTSI university partner campus).

Applications to this program are limited to \$100,000 per year for up to two (2) years in duration based on appropriate achievement of milestones and eventual submission of an extramural grant application.

Technology Enhancement Awards - 2016.07

SUBMISSION DEADLINE - FRIDAY, JULY 08, 2016 (5:00 PM).

A common critical gap in commercialization of technologies originating from the academic labs is the funding necessary to develop a robust commercialization relevant data package to reduce the risk of investment in early stage technologies. The Indiana CTSI and Indiana University School of Medicine through the office of the Associate Dean for Entrepreneurship and its Industry Collaboration Portal (ICP), are partnering with the newly created Indiana Center for Biomedical Innovation (ICBI) at IU Health to help fill this critical gap through a new support program, Technology Enhancement Awards (TEA), for early stage technologies. The technology may already reside in a start-up company or a clear plan exists to place it into a start-up. The New Program will partner with the highly successful SPARK program at Stanford University.

Indiana Drug Discovery Alliance - 2016.07

SUBMISSION DEADLINE - FRIDAY, JULY 01, 2016 (5:00 PM).

The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, seeks applications for a competitive program that will provide funds and essential consultation to support the early stage development of therapeutics. This opportunity is provided in concert with the Indiana Drug Discovery Alliance (IDDA), an advisory panel and clearinghouse for drug discovery and development resources at the Indiana-CTSI member institutions of Indiana University, Purdue University and the University of Notre Dame.

Call for Proposals: The Molecular Therapeutics Program will support the new collaborations and/or the use of core facilities that enable the translation of fundamental research related to drug discovery. Critical project feedback will be provided from a team of experienced industry and academic experts on the group's internal advisory committee, as well as through ad-hoc, project-specific pharmaceutical expert reviewers.

A detailed budget is not required at this time. Support projects will develop a budget of up to \$15,000 in consultation with the IDDA.

Strategic Pharma-Academic Research Consortium Awards Program - 2016.05

LETTER OF INTENT SUBMISSION DEADLINE - FRIDAY, MARCH 18, 2016

FULL PROPOSAL SUBMISSION DEADLINE - FRIDAY, JUNE 17, 2016

The Midwest Strategic Pharma-Academic Research Consortium (SPARC) has been established by the Indiana Clinical and Translational Sciences Institute. The members of the consortium consist of both academic and pharmaceutical companies. The inaugural CTSA members and pharmaceutical Companies are: Indiana University, Ohio State University, Northwestern University, Washington University in St. Louis, The University of Chicago, Eli Lilly and Co. and Takeda Pharmaceuticals Inc. SPARC is seeking applicants for the Midwest Strategic Pharma-Academic Research Consortium Awards Program. The consortium expects to support projects related to human autoimmune disease with the following criteria: (1) research is in the non-competitive space of mutual interest that address scientific and technological research challenges confronting the pharmaceutical industry; (2) project is to be executed with the network of Academic Members; (3) study is designed to further the understanding of disease biology, potentially leading to the identification of novel therapeutic targets; (4) to promote an improved definition of autoimmune disease according to molecular taxonomy rather than as clinical syndromes; and/or (5) to improve the prediction of response to therapy and the early detection of response / non-response in autoimmune diseases where this is not apparent at a clinical level. Successful proposals will demonstrate the following: A) Have at least **two (2)** Project Specific Personnel from different Academic Member institutions for which such institutions agree to contribute the requisite cost share funding for the research proposal. B) Address the non-competitive space of mutual interest to the Members and scientific and technological research challenges confronting translational research. C) Include the Research Plan and related budget for the study proposal. Applications to this program are limited to \$400,000 and are 24 months (2 years) in duration.

CHEP Community Based Research Awards - 2016.06

SUBMISSION DEADLINE - JUNE 1, 2016. (5:00 PM). The Indiana CTSI CHEP is soliciting proposals from applicants developing or currently involved in collaborative, community-based research projects. Namely, this RFA will fund pilot projects generated from community-university partnerships. The pilot project can serve a variety of purposes such as program evaluation, feasibility or preliminary data for extramural grant submissions, etc. Potential applicants are encouraged to identify, or further develop, collaborative relationships to be strengthened through this grant opportunity.

Adult Gastrointestinal and Liver Diseases Research Pilot Grant Program 2016.05

LETTER OF INTENT (LOI) DEADLINE - APRIL 15, 2016.

FULL SUBMISSION DEADLINE - MAY 2, 2016 (5:00 PM)

The Indiana Clinical and Translational Sciences Institute (CTSI) in conjunction with the Division of Gastroenterology/Hepatology in the Department of Medicine is soliciting proposals for pilot projects from investigators to develop and promote translational and transdisciplinary collaborative research projects in adult gastrointestinal and liver diseases. The objective is to fund studies that (a) establish or strengthen already established collaborations between faculty members in the GI Division and investigators from other departments and schools at IUSM, IUPUI and Purdue University; (b) generate preliminary data for extramural funding applications investigating adult GI and liver disorders.

The areas of interest include (a) acute and chronic liver diseases; (b) GI and hepatobiliary malignancy; (c) inflammatory bowel disease; (d) GI motility disorders; (e) chronic abdominal pain; and (f) chronic functional bowel disorders. The proposal should demonstrate tangible evidence that the collaboration will lead to a multiyear federal grant application.

Applications to this program are **limited to \$35,000** and are of **one (1) year duration**. Up to two grants will be awarded per grant cycle.

Pilot Funding For Research Use of Core Facilities - 2016.05

SUBMISSION DEADLINE - MAY 16, 2016. The Indiana CTSI Pilot Funding program is intended to promote the use of technologies and expertise afforded by the Indiana CTSI Core Facilities available at all partner institutions. Successful proposals will demonstrate outstanding scientific merit that can be linked to generating extramural funding or novel intellectual property (IP). Success of the program will be viewed, in part, by the fostering of new funded grants or providing significant contributions to grant renewals. Therefore, proposals will be judged with equal measure on scientific merit and the likelihood of generating new IP or extramural grant support.

Indiana CTSI/IUSM Core Equipment Funding - 2016.03

SUBMISSION DEADLINE EXTENDED - Original Date MARCH 25 has been extended to APRIL 22, 2016 (5:00 PM). The Indiana CTSI is seeking proposals from CTSI-Designated, IUSM-based Cores requesting support for the purchase of equipment that will enhance the research environment and contribute to the research mission of the School and the CTSI. Up to \$100,000 will be available through this solicitation. Proposals requesting \$5,000-\$100,000 will be accepted. Requests for equipment costing more than \$100,000 will be entertained if matching funds to cover the balance are identified.

Collaboration in Translational Research Pilot Grant Program - 2016.03

SUBMISSION DEADLINE - MARCH 4, 2016 (5:00 PM). The Indiana Clinical and Translational Science Institute (CTSI) is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP). Proposed projects should have participation by two (or more) principal investigators representing at least two of the sponsoring affiliates for this program. Sponsoring affiliates include: Indiana University School of Medicine (IUSM), IUPUI (non-IUSM), Indiana University-Bloomington, Purdue University-West Lafayette, and University of Notre Dame.

CTSI Postdoctoral Training Awards in Translational Research - 2016.02

SUBMISSION DEADLINE - FEBRUARY 1, 2016 (5:00 PM). The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices, or both. To be eligible, candidates must have received a PhD or equivalent degree from an accredited domestic or foreign institution. Please refer to the competition guidelines for full eligibility criteria.

CTSI Postdoc Challenge: Grand Funding to use CTSI-Designated Core Facilities - 2016.02

SUBMISSION DEADLINE - FEBRUARY 29, 2016 (5:00 PM). The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices.

CTSI-Designated Core Facilities are cores that undergo a yearly accreditation process through the Indiana CTSI for all partner institutions. The Postdoc Challenge offers postdoctoral research associates at Indiana University, Purdue University, and the University of Notre Dame valuable proposal writing and reviewing experience in areas related to translational research through the use of one or more of the CTSI-Designated Core Facilities at these universities. This is a competitive opportunity for two 1-year awards of \$5000 each per institution in the form of an expense account for use of core facility services. Funding is to be used only for services provided by the core facilities. Indiana CTSI-Designated Core Facilities are listed on the HUB (<https://www.indianactsi.org/servicecores>). If you are interested in participating, you must discuss your proposal with your advisor prior to beginning the application process to ensure your participation will be approved.

Support & Feedback

Citing CTSI

[Newsletter](#)

[Grants Login](#)

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [JUPUI](#); concept by [Tufts CTSI](#).
Copyright © 2014 Indiana CTSI

Contact:
info@indianactsi.org

Symposium, Workshop, and Conference Funding Program RFA

SUBMISSION DEADLINE - OPEN. The Indiana CTSI symposium, conference and workshop funding program is intended to facilitate sharing of ideas and findings in face-to-face discussion environments. The proposed symposium should include a translational research focus. The Indiana CTSI symposium program is specifically established to support presentation of new information to researchers in the Indiana CTSI that will establish research connections and lead to new research communication forums and ongoing collaborations. The application should describe how the proposed symposium will meet these goals.

[START](#)